Comparative mutant prevention concentration and antibacterial activity of fluoroquinolones against Escherichia coli in diarrheic buffalo calves

References

• Constable PD. Antimicrobial use in the treatment of calf diarrhea. J Vet Intern Med. 2004;18:8–17.
   PubMed Web of Science ®Google Scholar
• Aiello SE, Mays A. 1998. Intestinal diseases in ruminants. In: The Merck veterinary manual. 8th ed. Whitehouse Station, NJ: Merck & Co. 1998. p. 258–60.
   Google Scholar
• Everett MJ, Jin YF, Ricci V, Piddock LJ. Contributions of individual mechanisms to fluoroquinolone resistance in 36 Escherichia coli strains isolated from humans and animals. Antimicrob Agents Chemother. 1996;40:2380–6.
   PubMed Web of Science ®Google Scholar
• Bradford PA, Petersen PJ, Fingerman IM, White DG. Characterization of expanded spectrum cephalosporin resistance in E. coli isolates associated with bovine calf diarrhoeal disease. J Antimicrob Chemother. 1999;44:607–10.
   PubMed Web of Science ®Google Scholar
• Garau J, Xercavins M, Rodriguez-Carballeira M, Gomez-Vera JR, Coll I, Vidal D, et al. Emergence and dissemination of quinolone-resistant Escherichia coli in the community. Antimicrob Agents Chemother. 1999;43:2736–41.
   PubMed Web of Science ®Google Scholar
• Webber M, Piddock LJ. Quinolone resistance in Escherichia coli. Vet Res. 2001;32:623.
   Google Scholar
• Seiffert SN, Hilty M, Perreten V, Endimiani. An extended-spectrum cephalosporin-resistant Gram-negative organisms in livestock: an emerging problem for human health? Drug Resist Updat. 2013;16:22–45.
   PubMed Web of Science ®Google Scholar
• Urban C, Rahman N, Zhao X, Mariano N, Segal-Maurer S, Drlica K, et al. Fluoroquinolone-resistant Streptococcus pneumoniae associated with levofloxacin therapy. J Infect Dis. 2001;184:794–8.
   PubMed Web of Science ®Google Scholar
• Davidson R, Cavalcanti R, Brunton JL, Bast DJ, de Azavedo JC, Kibsey P, et al. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N Engl J Med. 2002;346:747–50.
   PubMed Web of Science ®Google Scholar
• Kays MB, Denys GA. Fluoroquinolone susceptibility, resistance and pharmacodynamics versus clinical isolates of Streptococcus pneumoniae from Indiana. Diagn Microbiol Infect Dis. 2001;40:193–8.
   PubMed Web of Science ®Google Scholar
• Ross JJ, Worthington MG, Gorbach SL. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N Engl J Med. 2002;347:65–7.
   PubMed Web of Science ®Google Scholar
• Hansen GT, Blondeau JM. Comparison of the minimum inhibitory, mutant prevention and minimum bactericidal concentrations of ciprofloxacin, levofloxacin and garenoxacin against enteric Gram-negative urinary tract infection pathogens. J Chemother. 2005;17:484–92.
   PubMed Web of Science ®Google Scholar
• Olofsson SK, Marcusson LL, Lindgren PK, Hughes D, Cars O. Selection of ciprofloxacin resistance in Escherichia coli in an in vitro kinetic model: relation between drug exposure and mutant prevention concentration. J Antimicrob Chemother. 2006;57:1116–21.
   PubMed Web of Science ®Google Scholar
• Linde HJ, Lehn N. Mutant prevention concentration of nalidixic acid, ciprofloxacin, clinafloxacin, levofloxacin, norfloxacin, ofloxacin, sparfloxacin or trovafloxacin for Escherichia coli under different growth conditions. J Antimicrob Chemother. 2004;53,:252–7.
   PubMed Web of Science ®Google Scholar
• Marcusson LL, Olofsson SK, Komp LP, Cars O, Hughes D. Mutant prevention concentrations of ciprofloxacin for urinary tract infection isolates of Escherichia coli. J Antimicrob Chemother. 2005;55:938–43.
   PubMed Web of Science ®Google Scholar
• Blondeau J, Zhao X, Hansen G, Drlica K. Mutant prevention concentrations (MPC) of fluoroquinolones with clinical isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother. 2001;45:433–8.
   PubMed Web of Science ®Google Scholar
• Smith HJ, Walters M, Hisanaga T, Zhanel GG, Hoban DJ. Mutant prevention concentrations for single-step fluoroquinolone-resistant mutants of wild-type, efflux-positive, or ParC or GyrA mutation-containing Streptococcus pneumoniae isolates. Antimicrob Agents Chemother. 2004;48:3954–8.
   PubMed Web of Science ®Google Scholar
• Hansen GT, Zhao X, Drlica K, Blondeau JM. Mutant prevention concentration for ciprofloxacin and levofloxacin with Pseudomonas aeruginosa. Int J Antimicrob Agents. 2006;27:120–4.
   PubMed Web of Science ®Google Scholar
• Lees P, Shojaee AF. Rational dosing of antimicrobial drugs: animals versus humans. Int J Antimicrob Agents. 2002;19:269–84.
   PubMed Web of Science ®Google Scholar
• McKellar QA, Sanchez, Bruni SF, Jones DG. Pharmacokinetic/pharmacodynamic relationships of antimicrobial drugs used in veterinary medicine. J Vet Pharmacol Ther. 2004;27:503–14.
   PubMed Web of Science ®Google Scholar
• Clinical Laboratory Standards Institute (CLSI). Development of in vitro susceptibility testing criteria and quality control parameters for veterinary antimicrobial agents. Approved guideline, 3rd edition M37-A3. Wayne, PA: CLSI; 2008.
   Google Scholar
• Sidhu PK, Landoni MF, Aliabadi MH, Toutain PL, Lees P. Pharmacokinetic and pharmacodynamic modelling of marbofloxacin administered alone and in combination with tolfenamic acid in calves. J Vet Pharmacol Ther. 2011;34:376–87.
   PubMed Web of Science ®Google Scholar
• Shojaee AF, Lees P. Pharmacokinetic-pharmacodynamic integration of danofloxacin in the calf. Res Vet Sci. 2003;74:247–59.
   PubMed Web of Science ®Google Scholar
• Gebru E, Choi MJ, Lee SJ, Damte D, Park SC. Mutant-prevention concentration and mechanism of resistance in clinical isolates and enrofloxacin/marbofloxacin-selected mutants of Escherichia coli of canine origin. J Med Microbiol. 2011;60:1512–22.
   PubMed Web of Science ®Google Scholar
• Blondeau JM. New concepts in antimicrobial susceptibility testing: the mutant prevention concentration and mutant selection window approach. Vet Dermatol. 2009;20:383–96.
   PubMed Web of Science ®Google Scholar
• Pasquali F, Manfreda G. Mutant prevention concentration of ciprofloxacin and enrofloxacin against Escherichia coli, Salmonella Typhimurium and Pseudomonas aeruginosa. Vet Microbiol. 2007;119:304–10.
   PubMed Web of Science ®Google Scholar
• Credito K, Kosowska-Shick K, McGhee P, Pankuch GA, Appelbaum PC. Comparative study of the mutant prevention concentrations of moxifloxacin, levofloxacin and gemifloxacin against Pneumococci. Antimicrob Agents Chemother. 2010;54:2673–7.
   Google Scholar
• Toutain PL. Antibiotic treatment of animals–a different approach to rational dosing. Vet J. 2003;165:98–100.
   PubMed Web of Science ®Google Scholar
• Blondeau JM, Borsos S, Blondeau LD, Blondeau BJ, Hesje CE. Comparative minimum inhibitory and mutant prevention drug concentrations of enrofloxacin, ceftiofur, florfenicol, tilmicosin and tulathromycin against bovine clinical isolates of Mannheimia haemolytica. Vet Microbiol. 2012;160:85–90.
   PubMed Web of Science ®Google Scholar
• Martinez MN, Papich MG, Drusano GL. Dosing regimen matters: the importance of early intervention and rapid attainment of the pharmacokinetic/pharmacodynamic target. Antimicrob Agents Chemother. 2012;56: 2795–805.
   PubMed Web of Science ®Google Scholar
• Bartoloni A, Bartalesi F, Mantella A, Dell’Amico E, Roselli M, Strohmeyer M, et al. High prevalence of acquired antimicrobial resistance unrelated to heavy antimicrobial consumption. J Infect Dis. 2004;189:1291–4.
   PubMed Web of Science ®Google Scholar
• Singer RS, Patterson SK, Wallace RL. Effects of therapeutic ceftiofur administration to dairy cattle on Escherichia coli dynamics in the intestinal tract. Appl Environ Microbiol. 2008;74:6956–62.
   PubMed Web of Science ®Google Scholar
• Balaje RM, Sidhu PK, Kaur G, Rampal S. Mutant prevention concentration and PK–PD relationships of enrofloxacin for Pasteurella multocida in buffalo calves. Res Vet Sci. 2013;95(3):1114–24.
   PubMed Web of Science ®Google Scholar
• Orden JA, Ruiz-Santa-Quiteria JA, Garcia S, Cid D, De La Fuente R. In vitro activities of cephalosporins and quinolones against Escherichia coli strains isolated from diarrheic dairy calves. Antimicrob Agents Chemother. 1999;43:510–3.
   PubMed Web of Science ®Google Scholar